Production and synthetic modifications of shikimic acid

NR Candeias, B Assoah, SP Simeonov - Chemical reviews, 2018 - ACS Publications
Shikimic acid is a natural product of industrial importance utilized as a precursor of the
antiviral Tamiflu. It is nowadays produced in multihundred ton amounts from the extraction of …

Mycobacterium tuberculosis Shikimate Pathway Enzymes as Targets for the Rational Design of Anti-Tuberculosis Drugs

JES Nunes, MA Duque, TF de Freitas, L Galina… - Molecules, 2020 - mdpi.com
Roughly a third of the world's population is estimated to have latent Mycobacterium
tuberculosis infection, being at risk of developing active tuberculosis (TB) during their …

In vitro and in silico analysis of the Anopheles anticholinesterase activity of terpenoids

TA Rants'o, LL Koekemoer, RL van Zyl - Parasitology International, 2023 - Elsevier
Abstract Anopheles gambiae, An. coluzzii, An. arabiensis, and An. funestus are major
vectors in high malaria endemic African regions. Various terpenoid classes form the main …

Be Aware of Aggregators in the Search for Potential Human ecto-5′-Nucleotidase Inhibitors

LG Viviani, E Piccirillo, A Cheffer, L De Rezende… - Molecules, 2018 - mdpi.com
Promiscuous inhibition due to aggregate formation has been recognized as a major concern
in drug discovery campaigns. Here, we report some aggregators identified in a virtual …

Theoretical characterization of the shikimate 5-dehydrogenase reaction from Mycobacterium tuberculosis by hybrid QC/MM simulations and quantum chemical …

IB Grillo, JFR Bachega, LFSM Timmers… - Journal of Molecular …, 2020 - Springer
In this study, we have investigated the enzyme shikimate 5-dehydrogenase from the
causative agent of tuberculosis, Mycobacterium tuberculosis. We have employed a mixture …

Multitargeting: An Alternative Approach to Tackle Multidrug Resistance in Tuberculosis

S Hazra, R Hazarika, S Patra - Current Drug Targets, 2023 - ingentaconnect.com
Background: The prevalence of drug-resistant organisms has steadily increased over the
past few decades worldwide. Especially in tuberculosis (TB) disease, the problems of co …

Target discovery for new antitubercular drugs using a large dataset of growth inhibitors from PubChem

RC Goldman - … Disorders-Drug Targets (Formerly Current Drug …, 2020 - ingentaconnect.com
The number of drugs available for treatment of active tuberculosis is diminishing due to
increased multidrug resistance selection in Mycobacterium tuberculosis leading to multiple …

[HTML][HTML] 以莽草酸激酶为靶点的新型抗结核先导化合物的发现

王霞, 朱宁屿, 姜威, 司书毅 - 药学学报, 2018 - html.rhhz.net
莽草酸激酶是莽草酸途径中的关键蛋白, 对结核分枝杆菌的生存至关重要.
本研究首先建立了结核分枝杆菌莽草酸激酶(Mycobacterium tuberculosis shikimate kinase …

Pharmacokinetic and Molecular docking studies of Centella asiatica phytocompounds to explore potential anti-tuberculosis activity

N Sarkar, D Som, S Mahanta, B Tanti… - International Journal of …, 2024 - journal.nielit.edu.in
Tuberculosis is caused by the bacterium Mycobacterium tuberculosis. The first line drugs
available for treatment of TB are isoniazid, rifamsin etc. Second line drugs are …

Transition from classical methods to new strategies: Mechanistic evaluation of inhibitors against Mycobacterium tuberculosis shikimate kinase

NR Fuanta - 2018 - search.proquest.com
Tuberculosis (TB) still stands as one of the leading causes of mortality resulting from an
infectious agent. In part, this stems from the emergence of multidrug and extensive drug …